Umbilical cord blood derived cellular therapy: advances in clinical development

Frontiers in Oncology

Oncology

Jiasheng Wang¹  Leland Metheny¹ 

[1] Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, United States;

关键词: cord blood;    chimeric antigen receptor;    hematopoietic stem cell transplantation;    NK-cells;    mesenchymal stem cells;   

DOI  :  10.3389/fonc.2023.1167266

 received in 2023-02-16, accepted in 2023-05-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

While cord blood (CB) is primarily utilized in allogeneic hematopoietic cell transplantation (HCT), the development of novel cell therapy products from CB is a growing and developing field. Compared to adult blood, CB is characterized by a higher percentage of hematopoietic stem cells (HSCs) and progenitor cells, less mature immune cells that retain a high capacity of proliferation, and stronger immune tolerance that requires less stringent HLA-matching when used in the allogenic setting. Given that CB is an FDA regulated product and along with its unique cellular composition, CB lends itself as a readily available and safe starting material for the development of off-the-shelf cell therapies. Moreover, non-hematologic cells such as mesenchymal stem cell (MSCs) residing in CB or CB tissue also have potential in regenerative medicine and inflammatory and autoimmune conditions. In this review, we will focus on recent clinical development on CB-derived cellular therapies in the field of oncology, including T-cell therapies such as chimeric antigen receptor (CAR) T-cells, regulatory T-cells, and virus-specific T-cells; NK-cell therapies, such as NK cell engagers and CAR NK-cells; CB-HCT and various modifications; as well as applications of MSCs in HCT.

【 授权许可】

Unknown   
Copyright © 2023 Wang and Metheny